| Literature DB >> 31783479 |
Silvia Carvajal1, Meritxell Perramón1, Gregori Casals1, Denise Oró1, Jordi Ribera1, Manuel Morales-Ruiz1,2, Eudald Casals3, Pedro Casado4, Pedro Melgar-Lesmes1,2, Guillermo Fernández-Varo1,2, Pedro Cutillas4, Victor Puntes5,6,7, Wladimiro Jiménez1,2.
Abstract
Cerium oxide nanoparticles (CeO2NPs) possess powerful antioxidant properties, thus emerging as a potential therapeutic tool in non-alcoholic fatty liver disease (NAFLD) progression, which is characterized by a high presence of reactive oxygen species (ROS). The aim of this study was to elucidate whether CeO2NPs can prevent or attenuate oxidant injury in the hepatic human cell line HepG2 and to investigate the mechanisms involved in this phenomenon. The effect of CeO2NPs on cell viability and ROS scavenging was determined, the differential expression of pro-inflammatory and oxidative stress-related genes was analyzed, and a proteomic analysis was performed to assess the impact of CeO2NPs on cell phosphorylation in human hepatic cells under oxidative stress conditions. CeO2NPs did not modify HepG2 cell viability in basal conditions but reduced H2O2- and lipopolysaccharide (LPS)-induced cell death and prevented H2O2-induced overexpression of MPO, PTGS1 and iNOS. Phosphoproteomic analysis showed that CeO2NPs reverted the H2O2-mediated increase in the phosphorylation of peptides related to cellular proliferation, stress response, and gene transcription regulation, and interfered with H2O2 effects on mTOR, MAPK/ERK, CK2A1 and PKACA signaling pathways. In conclusion, CeO2NPs protect HepG2 cells from cell-induced oxidative damage, reducing ROS generation and inflammatory gene expression as well as regulation of kinase-driven cell survival pathways.Entities:
Keywords: NAFLD; cerium oxide nanoparticles; human hepatic cells; oxidative stress; phosphoproteomics
Mesh:
Substances:
Year: 2019 PMID: 31783479 PMCID: PMC6928882 DOI: 10.3390/ijms20235959
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Characterization of the CeO2NPs used in this work. (A) NPs after purification and resuspension in Tetramethylammonium hydroxide (TMAOH) 10 mM. Scale bar is 50 nm. (B) NPs after 2 days in Cell Culture Medium (CCM), Dulbecco’s Modified Eagle Medium (DMEM) + 10% Fetal Calf Serum (FCS). Scale bar is 50 nm. Although TEM images of the NPs in the CCM are not as clear as in TMAOH, due to the presence of other components of the media, NPs can still be observed and measured. (C) Evolution of the UV-VIS spectra of CeO2NPs in the CCM. NPs are stable throughout the time of the experiments and presence of large agglomerates can be ruled out since those agglomerates would increase the absorbance at larger wavelengths. (D) and (E) Size distribution using ImageJ free software (Available online: https://imagej.nih.gov/ij/) counting more than 500 NPs of different TEM images of the NPs in TMAOH and in CCM. A slight increase can be observed in the size distribution (standard deviation increases from 1.2 to 2.0) probably due to dissolution of NPs in the more aggressive media of the CCM. However, after 2 days, mean size is unaltered. (F) X-ray Diffraction (XRD) spectra of the CeO2NPs in TMAOH 10 mM showing the characteristic peaks of CeO2 crystals.
Dynamic light scattering (DLS) and Zeta potential (Z-Pot) values of CeO2NPs purified and resuspended in TMAOH 10 mM and after exposure to DMEM + 10% FCS (CCM). A decrease of the Z-Potential towards the value of the FCS (Z-Pot = −10 mV) and an increase of the hydrodynamic diameter due to the absorption of proteins can be observed. The increase of DLS and maintenance of size distribution observed by TEM images after 2 days in CCM is an indication of the stability of the NPs and the protein corona formation in the CCM.
| CeO2NPs (TEM = 4–5 nm) | ||
|---|---|---|
| Table Header | DLS (Z-average, nm) | Z-Pot (mV) |
| NPs after purification | 33.0 | −47.0 |
| 0 d in cCCM | 70 | −35.4 |
| 1 d in cCCM | 70 | −36.4 |
| 2 d in cCCM | 72.9 | −35.0 |
| 15 d in cCCM | 79 | −16.9 |
| 30 d in cCCM | 100.2 | −9.6 |
Figure 2CeO2NPs inhibited H2O2-induced cytotoxicity in HepG2 cells. (A) Viability of HepG2 cells after treatment with CeO2NPs (10 µg/mL) determined using the MTS assay (MTS) at indicated time points. Quadruplicates of each group were used in each independent experiment. The results are expressed as percentage of control cells for the times indicated. (B) HepG2 cells were exposed to 1.5 mM H2O2 and treated with 10 µg/mL of CeO2NPs for 1.5 h. Cell viability was detected using MTS and expressed as percentage of control cells. Data are the mean ± S.E. of triplicate experiments. ** p < 0.01 vs. control. + presence; − absence. (C) Representative phase contrast light microscopy images of HepG2 cells at 1.5 h after H2O2 treatment. (D) Reactive oxygen species (ROS) production was determined by fluorescence spectrophotometry using the oxidant-sensitive dye 2’,7’-DCF-HDA. The results were expressed as percentage of control cells for the treatments indicated. *** p < 0.001 vs. control; †† p < 0.01 vs. H2O2. + presence; − absence. (E) Representative microphotographs of DFC fluorescence (DCF, green) and 4’,6-diamidino-2-phenylindole (DAPI, blue) after H2O2 treatment (original magnification, 200×).
Figure 3CeO2NPs reduced lipopolysaccharide (LPS)-induced ROS production and cytotoxicity in HepG2 cells. (A) Cells were treated with 10 µg/mL LPS for 2 h in the presence of CeO2NPs (10 µg/mL) or vehicle. Extracellular ROS production was determined by fluorescence spectrophotometry using the oxidant-sensitive dye 2’,7’-DCF-DA. The results were expressed as percentage of control cells for the indicated treatments. Data are mean ± S.E. *** p < 0.001. (B) HepG2 cells were exposed to 10 µg/mL LPS and treated with 10 µg/mL CeO2NPs or vehicle for 24 h. Cell viability was detected using MTS and expressed as percentage of control cells. Data are the mean ± S.E, *** p < 0.001; + presence; − absence.
Messenger expression of genes involved in oxidative stress and antioxidant defense in HepG2 cells exposed to H2O2.
| Genes | H2O2 ( | H2O2 + CeO2NPs ( |
|---|---|---|
|
| ||
|
| −2.06 ** | −2.67 *** |
|
| −2.01 * | −2.25 *** |
|
| 3.54 | 1.72 |
|
| 5.32 * | 1.54 *† |
|
| 3.13 | 1.78 |
|
| 3.69 * | 1.07 † |
|
| −3.28 ** | −6.30 *** |
|
| 3.99 ** | 2.91 ** |
|
| 3.07 * | 2.16 |
|
| ||
|
| 2.59 * | 1.38 * |
|
| 1.11 | −1.89 † |
|
| −2.30 * | −4.04 *** |
|
| −3.51 *** | −4.36 *** |
|
| ||
|
| −2.66 ** | −3.36 *** |
|
| 8.30 * | 9.39 * |
|
| −3.20 ** | −3.44 *** |
|
| 3.29 *** | 3.42 *** |
|
| 3.86 ** | 2.30 * |
|
| 2.68 | 3.15 |
|
| 5.28 * | 2.42 |
|
| −3.32 * | −2.6 ** |
|
| −2.08 *** | −2.64 *** |
|
| −5.11 ** | −7.08 ** |
|
| −4.19 *** | −4.41 *** |
|
| ||
|
| −5.88 * | −5.84 ** |
CAT: catalase; GPX7: glutathione peroxidase 7; LPO: lactoperoxidase; MPO: myeloperoxidase; TTN: titin; PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase); SOD3: superoxide dismutase 3; SRXN1: sulfiredoxin 1 homolog; TXNRD1: thioredoxin reductase 1; NCF1: neutrophil cytosolic factor 1; NCF2: neutrophil cytosolic factor 2; UCP2: uncoupling protein 2 (mitochondrial, proton carrier); EPHX2: epoxide hydrolase 2, cytoplasmic; DCHR24: 24-dehydrocholesterol reductase; DUSP1: dual specificity phosphatase 1; FOXM1: forkhead box M1; GCLC: glutamate-cysteine ligase, catalytic subunit; GCLM: glutamate cysteine ligase, modifier subunit; HMOX1: heme oxygenase (decycling) 1; HSPA1A: heat shock 70kDa protein 1A; MBL2: mannose-binding lectin (protein C) 2, soluble; OXR1: oxidation resistance 1; SCARA3: scavenger receptor class A, member 3; SEPP1: selenoprotein P, plasma, 1; MB: myoglobin. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control; † p < 0.05 vs. H2O2 + CeO2NPs (unpaired Student’s t-test).
Figure 4A volcano plot representation of the differentially expressed genes in a pair-wise comparison of untreated and CeO2NP-treated H2O2-exposed HepG2 cells. Significance was set to a p value based on a Student’s t-test of 0.05 [−log10 (p-value) ≥ 1.30], the biological cut-off was set to a fold regulation of ± 2 fold [−1 ≥ log2 (FC of H2O2+CeO2NPs/H2O2) ≥ 1]. In accordance with these two criteria, the top seven deferentially expressed genes are labeled with their corresponding gene ID. The different color codes used represent insignificant genes (grey), both biologically and statistically significant down-regulated genes (green) and statistically but not biologically significant down-regulated genes (orange) in CeO2NP treated cells.
Figure 5Effect of CeO2NPs on the expression of oxidative stress-related genes in HepG2 cells exposed to H2O2. Cells were stimulated with 1.5 mM H2O2 for 24 h and incubated in the absence or presence of CeO2NPs (10 µg/mL). The messenger RNA expression of MPO and PTGS1 was assessed using real-time PCR. Data are the mean + S.E. of triplicate experiments. * p < 0.05; ** p < 0.01 vs. control; †† p < 0.01 vs. H2O2.
Figure 6Effect of CeO2NPs on the expression of pro-inflammatory genes in HepG2 cells exposed to H2O2. Cells were stimulated with 1.5 mM H2O2 for 6 and 24 h and incubated in the absence or presence of CeO2NPs (10 µg/mL). The messenger RNA expression of iNOS and TNF-α was then assessed using real-time PCR. Data are the mean ± S.E. of triplicate experiments. * p < 0.05; ** p < 0.01; *** p < 0.001.
Figure 7Effect of CeO2NPs on the modulation of kinase activity in HepG2 cells exposed to H2O2. (A) Volcano plot showing the fold difference between H2O2-exposed HepG2 cells treated or not with CeO2NPs for 1 h. Fold difference in peptide abundance is represented as the log2 (a positive value for the log2 of the fold difference indicates the increased abundance of a phosphorylated peptide after CeO2NPs treatment) and p value as −log10 (a significance −log10 p value > 2 corresponds to a linear p value of < 0.01). (B) Heatmap showing the enrichment of substrate groups for the different kinases calculated by the KSEA algorithm with the PhosphoSite database and the z-score method of calculating enrichment. The extent of enrichment was calculated as the abundance of substrate phosphorylation peptide in HepG2 cells under one condition divided by its abundance in another condition. Specifically, the first column shows the result of KSEA for cells exposed to H2O2 vs. control cells treated with vehicle, the second column shows KSEA of cells exposed to H2O2 and CeO2NPs vs. control treated with vehicle, and the third column shows KSEA of cells exposed to H2O2 and CeO2NPs vs. HepG2 exposed to H2O2. Column “q” indicates the number of phosphopeptides used to estimate the enrichment in kinase activity for the indicate kinase. An arbitrary cut-off value of 6 phosphopeptides has been used. (C) Heatmap showing phosphopeptides significantly affected by exposure of HepG2 cells to H2O2 and H2O2 + CeO2NPs in proteins linked to mTOR, ERK, CK2A1 and PKA signaling pathways. Statistical significant was assessed using t-test in (A,C) or z-test (B). * p < 0.05; ** p < 0.01; *** p < 0.001.
Phosphopeptides with significantly decreased phosphorylation with a Log2 fold ≤ −2 after treatment with CeO2NPs in HepG2 cells exposed to H2O2.
| Protein | Phosphopeptide | H2O2 vs Control. Fold | H2O2 + NPs vs H2O2 Fold |
|---|---|---|---|
| AT-rich interactive domain-containing protein 1A | ARID1A seq: 1182–1202 + Phospho (ST) | 3.0099 * | −2.727 * |
| Charged multivesicular body protein 2b | CHMP2B pS199 | 9.963 * | −9.964 * |
| C-Jun-amino-terminal kinase-interacting protein 4 | SPAG9 seq: 223–241 + Phospho (ST) | 10.117 * | −10.11 * |
| Deoxynucleotidyltransferase terminal-interacting protein 2 | DNTTIP2 pS141 | 10.135 * | −10.13 * |
| DNA replication licensing factor MCM3 | MCM3 seq: 696–724 + Gln- > pyro-Glu (N-term Q); Phospho (ST) | 8.390 * | −8.391 * |
| DNA-dependent protein kinase catalytic subunit | PRKDC seq: 3197–3232 + Phospho (ST) | 8.6913 * | −8.692 * |
| Double-stranded RNA-binding protein Staufen homolog 1 | STAU1 pS390 | 8.9250 * | −8.926 * |
| E3 ubiquitin-protein ligase UBR5 | UBR5 seq: 636–654 + Phospho (ST) | 10.128 * | −10.12 * |
| Eukaryotic translation initiation factor 4E-binding protein 1 | EIF4EBP1 pS65 pT70 | 10.841 * | −10.84 * |
| Kanadaptin | SLC4A1AP pS466 | 9.2633 * | −9.264 * |
| Kanadaptin | SLC4A1AP seq: 324–362 + Oxidation (M); Phospho (ST) | 9.164 * | −9.165 * |
| MKL/myocardin-like protein 2 | MKL2 seq: 535–562 + Phospho (ST) | 9.971 * | −9.973 * |
| Pericentriolar material 1 protein | PCM1 seq: 1923–1972 + Phospho (ST); Phospho (Y) | 10.677 * | −10.67 * |
| Prolyl 3-hydroxylase OGFOD1 | OGFOD1 seq: 381–427 + Phospho (ST) | 9.012 * | −9.013 * |
| Protein PRRC2A | PRRC2A seq: 1103–1128 + Gln- > pyro-Glu (N-term Q); Phospho (ST) | 9.2358 * | −9.236 * |
| R3H domain-containing protein 1 | R3HDM1 seq: 295–314 + Phospho (ST) | 8.592 * | −8.593 * |
| Ras-responsive element-binding protein 1 | RREB1 seq: 1636–1665 + Phospho (ST) | 9.296 * | −9.297 * |
| Stress-70 protein. mitochondrial | HSPA9 pM370 pM389 | 11.353 * | −11.35 * |
| Telomeric repeat-binding factor 2 | TERF2 seq: 404–447 + Phospho (ST) | 8.8833 * | −8.884 * |
| Transcriptional coactivator YAP1 | YAP1 seq: 162–181 + Gln- > pyro-Glu (N-term Q); Phospho (ST) | 3.3580 * | −5.372 * |
| Apoptotic chromatin condensation inducer in the nucleus | ACIN1 seq: 463–506 + 3 Phospho (ST) | 5.9139 * | −11.89 ** |
| Paxillin | PXN seq: 298–317 + Phospho (ST) | 1.8510 * | −2.535 ** |
| Poly(rC)-binding protein 1 | PCBP1 pM186 pS190 | 1.9716 * | −2.646 ** |
| Nascent polypeptide-associated complex subunit alpha | NACA pS2029 | 1.284 * | −3.119 ** |
| RNA-binding protein 25 | RBM25 pS703 | 11.804 * | −4.246 ** |
| Phosphoribosyl pyrophosphate synthase-associated protein 1 | PRPSAP1 seq: 193–220 + Oxidation (M); Phospho (ST) | 12.440 ** | −4.758 * |
| Serine/arginine repetitive matrix protein 2 | SRRM2 seq: 2275–2301 + Phospho (ST) | 9.8054 ** | −9.80 * |
| Cell division cycle protein 23 homolog | CDC23 pT562 | 8.7452 ** | −8.746 ** |
| Centrosomal protein of 131 kDa | CEP131 seq: 45–56 + Phospho (ST) | 9.3197 ** | −9.320 ** |
| Deoxynucleotidyltransferase terminal-interacting protein 2 | DNTTIP2 pS381 | 9.412 ** | −9.41 ** |
| Nuclear receptor coactivator 2 | NCOA2 pS771 | 2.5932 ** | −2.630 ** |
| Oxysterol-binding protein 1 | OSBP seq: 377–395 + 2 Phospho (ST) | 2.8700 ** | −2.558 ** |
| RNA-binding motif protein. X chromosome | RBMX pS208 | 9.8237 ** | −9.824 ** |
| Transcription factor Sp5 | SP5 seq: 43–68 + Phospho (ST) | 4.5004 ** | −10.69 ** |
| Uncharacterized protein C6orf106 | C6orf106 seq: 264–287 + Phospho (ST) | 8.2914 ** | −2.875 ** |
| Epsin-1 | EPN1 seq: 412–445 + Phospho (ST) | 13.834 ** | −4.391 *** |
| Pinin | PNN pS66 | 8.894 *** | −4.875 * |
| Protein LYRIC | MTDH pS298 | 8.390 *** | −8.391 ** |
| POU domain. class 2. transcription factor 1 | POU2F1 seq: 273–293 + Phospho (ST) | 8.691 *** | −8.69 *** |
Statistical significance was assessed using the t-test. *. p < 0.05; **. p < 0.01; ***. p < 0.001.